Aveo Oncology Inc. CEO Michael Bailey told BioWorld that the positive opinion from the EMA's Committee for Medicinal Products for Human Use on approval of Fotivda (tivozanib) in advanced renal cell carcinoma is "really just the beginning" of the drug's revival. "It's a great first chapter," he said, to be followed by efforts for approval in North America and combination-drug experiments.